相关实验视频
Updated: Jun 4, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.5K
(Bixaceae) 种子作为生物活性化合物的潜在来源,可以调节食后高血糖症
Jonatan Jafet Uuh Narvaez1, José A Guerrero-Analco2, Juan Luis Monribot-Villanueva2
1Facultad de Ingeniería Química, Universidad Autónoma de Yucatán, Mérida, Mexico.
Journal of the science of food and agriculture
|December 21, 2024
概括
比克萨奥雷拉纳提取物有效地抑制了与高血糖相关的酶. 酸和纳灵宁等关键化合物显示出治疗后食高血糖症和糖尿病的治疗潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 餐后高血糖 (PHG) 的管理依赖于α-amylase (α-AMY) 和α-glucosidase (α-GLU) 抑制剂.
- 比克萨奥雷拉纳 (annatto) 含有生物活性化合物,对这些酶具有潜在的抑制作用.
- 了解B. orellana的抑制机制和代谢概况对于其治疗应用至关重要.
研究的目的:
- 阐明Bixa orellana提取物 (BOE) 对α-AMY和α-GLU的抑制机制.
- 用代谢学来识别和量化BOE中的生物活性化合物.
- 通过in silico方法评估这些化合物与酶的相互作用.
主要方法:
- 酶抑制试验用于确定IC50值和抑制类型.
- 非向和向的代谢学,用于化合物识别和量化.
- 在基分子对接,以评估与酶活性位点的结合亲缘关系.
主要成果:
- 博伊证明了α-AMY和α-GLU的混合和竞争性抑制.
- 代谢学发现了36种假定化合物,包括脂肪酸,并量化了18种关键化合物,如酸和纳灵宁.
- 在分析中确定了桑托安格罗尔,诺比克辛,米瑞和26-基布拉西诺利德具有较高的结合亲缘关系.
结论:
- 比克萨奥雷拉纳提取物有效抑制α-AMY和α-GLU.
- 酸,纳灵宁,桑托安格罗尔,诺比克辛和26-基布拉西诺利德被确定为关键的生物活性贡献者.
- 这些发现支持BOE在管理PHG和糖尿病方面的潜力.
相关概念视频
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
155
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
155
Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Glucose Absorption Into the Small Intestine
31.3K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.3K
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136

